American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 1089-1097 , December 2009

Ascorbic Acid for Anemia Management in Hemodialysis Patients: A Systematic Review and Meta-analysis

  • Vinay Deved, MD

      Affiliations

    • Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    • Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
    • ,
  • Penelope Poyah, MD

      Affiliations

    • Department of Medicine, Dalhouise University, Halifax, Nova Scotia, Canada
    • ,
  • Matthew T. James, MD

      Affiliations

    • Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    • Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
    • ,
  • Marcello Tonelli, MD, SM

      Affiliations

    • Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Braden J. Manns, MD, MSc

      Affiliations

    • Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    • Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
    • ,
  • Michael Walsh, MD

      Affiliations

    • Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    • Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
    • ,
  • Brenda R. Hemmelgarn, MD, PhD

      Affiliations

    • Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    • Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
    • Corresponding Author InformationAddress correspondence to Brenda R. Hemmelgarn, MD, PhD, Division of Nephrology, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada T2N 2T9
    • ,
  • Alberta Kidney Disease Network

Received 23 March 2009 ,Accepted 29 June 2009.

References 

  1. Sunder-Plassmann G, Horl WH. Erythropoietin and iron. Clin Nephrol. 1997;47(3):141–157
  2. Locatelli F, Aljama P, Barany P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):S1–S47
  3. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;2(8517):1175–1178
  4. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease (Results of a phase III multicenter clinical trial). Ann Intern Med. 1989;111(12):992–1000
  5. Tarng DC, Huang TP, Doong TI. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin. Nephron. 1998;78(3):253–259
  6. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58(3):1325–1335
  7. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant. 2005;20(suppl 3):S3–S24
  8. Tarng DC, Huang TP, Chen TW, Yang WC. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int. 1999;55(suppl 69):S107–S118
  9. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S1–S145
  10. Bridges KR, Hoffman KE. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem. 1986;261(30):14273–14277
  11. Goldberg A. The enzymic formation of haem by the incorporation of iron into protoporphyrin; importance of ascorbic acid, ergothioneine and glutathione. Br J Haematol. 1959;5:150–157
  12. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant. 1995;10(suppl 6):S44–S47
  13. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant. 1998;13(11):2867–2872
  14. Wyndham R, Sapir DG. Effects of vitamin C on anemia and iron metabolism in patients on maintenance haemodialysis. Aust N Z J Med. 1980;10:488
  15. Lin CL, Hsu PY, Yang HY, Huang CC. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Ren Fail. 2003;25(3):445–453
  16. Canavese C, Petrarulo M, Massarenti P, et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis. 2005;45(3):540–549
  17. McConnell KN, Rolton HA, Modi KS, Macdougall AI. Plasma oxalate in patients with chronic renal failure receiving continuous ambulatory peritoneal dialysis or hemodialysis. Am J Kidney Dis. 1991;18(4):441–445
  18. Costello JF, Sadovnic MJ, Cottington EM. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol. 1991;1(12):1289–1298
  19. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354(9193):1896–1900
  20. Weatherall MS, Sherry KM. An evaluation of the Spuncrit infra-red analyser for measurement of haematocrit. Clin Lab Haematol. 1997;19(3):183–186
  21. Higgins JPT, Deeks JJ, Altman DG Cochrane Statistical Methods Group. Special topics in statistics; Chapter 16. Version 5.0.1 [updated September 2008] In:  Higgins JPT,  Green S editor. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2008;Available from www.cochrane-handbook.org. Accessed September 1, 2009
  22. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol. 2006;59(4):342–353
  23. Thiessen PH, Barrowman N, Garg AX. Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation. J Clin Epidemiol. 2007;60(3):228–240
  24. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31(1):140–149
  25. Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed.. London: BMJ Publishing Group; 2001;
  26. Sezer S, Ozdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artif Organs. 2002;26(4):366–370
  27. Deira J, Diego J, Martinez R, et al. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol. 2003;16(5):703–709
  28. Chan D, Irish A, Dogra G. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology. 2005;10(4):336–340
  29. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 2006;47(4):644–654
  30. Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol. 2000;13(6):444–449
  31. Keven K, Kutlay S, Nergizoglu G, Erturk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis. 2003;41(6):1233–1239
  32. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18(3):975–984
  33. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19(2):372–379
  34. Ali M, Fayemi AO, Rigolosi R, Frascino J, Marsden T, Malcolm D. Hemosiderosis in hemodialysis patients (An autopsy study of 50 cases). JAMA. 1980;244(4):343–345
  35. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant. 1990;5(2):130–134
  36. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381–388
  37. Lipschitz DA, Bothwell TH, Seftel HC, Wapnick AA, Charlton RW. The role of ascorbic acid in the metabolism of storage iron. Br J Haematol. 1971;20(2):155–163
  38. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. 1999;55(6):2477–2486
  39. Canavese C, Petrarulo M, Massarenti P, et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis. 2005;45(3):540–549
  40. Pru C, Eaton J, Kjellstrand C. Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron. 1985;39(2):112–116
  41. Morgan SH, Maher ER, Purkiss P, Watts RW, Curtis JR. Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine. Nephrol Dial Transplant. 1988;3(1):28–32
  42. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140(7):533–537

 Originally published online as doi:10.1053/j.ajkd.2009.06.040 on September 24, 2009.

PII: S0272-6386(09)00988-3

doi: 10.1053/j.ajkd.2009.06.040

American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 1089-1097 , December 2009

Article Tools

* Image Usage & Resolution